Patent · US Active

Polymorphs and uses thereof

US11214536B2 · kind B2 · utility

2Cited by
50References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 20, 2018
Grant dateJan 4, 2022
Priority date
Expiry dateNov 20, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to new polymorphs of LXRβ agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRβ agonist, as well as methods of treating cancer including administration of a formulation including an LXRβ agonist to a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.